Aethlon Medical
AEMD
#10510
Rank
HK$21.91 M
Marketcap
HK$28.79
Share price
-8.19%
Change (1 day)
21.73%
Change (1 year)
Categories

P/E ratio for Aethlon Medical (AEMD)

P/E ratio as of December 2025 (TTM): -0.5920

According to Aethlon Medical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.592. At the end of 2025 the company had a P/E ratio of -0.3450.

P/E ratio history for Aethlon Medical from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2025-0.3450-3.11%
2024-0.3561-44.72%
2023-0.6441-69.31%
2022-2.10-32.8%
2021-3.12271.98%
2020-0.8396-67.74%
2019-2.600.59%
2018-2.59-28.69%
2017-3.63-55%
2016-8.06-18.05%
2015-9.84256.17%
2014-2.76-24.68%
2013-3.67193.33%
2012-1.25-28.57%
2011-1.75-64.06%
2010-4.87150.5%
2009-1.94-62.98%
2008-5.2533.68%
2007-3.93-27.38%
2006-5.41114.55%
2005-2.52-73.76%
2004-9.61704.27%
2003-1.19-54.16%
2002-2.6128.07%
2001-2.03

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Inovio Pharmaceuticals
INO
-0.7188 21.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Coherent Corp.
COHR
239-40,504.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Bruker
BRKR
-300 50,607.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Pacific Biosciences
PACB
-1.41 137.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Accelerate Diagnostics
AXDX
-0.0192-96.76%๐Ÿ‡บ๐Ÿ‡ธ USA
PerkinElmer
PKI
15.0-2,628.14%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.